TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33073938
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg every night for three months
Study: 35216750
Drug: Open-loop system
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop system (sensor-augmented pump therapy)
Study: 32386001
Drug: Early goal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early goal directed sedation (EGDS) with continuous intravenous infusion of dexmedetomidine (initial dose of 0.2 μg×kg‐1×min‐1) for 72 hours
Study: 32386001
Drug: Standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation (STD) with intravenous bolus of propofol
Study: 32223108
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills (QLP), 6 g tid for 6 months
Study: 32223108
Drug: Placebo control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control, 6 g tid for 6 months
Study: 36458443
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T) of apixaban 2.5 mg under fasting conditions
Study: 36458443
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T) of apixaban 2.5 mg under fed conditions
Study: 36458443
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (R) of apixaban 2.5 mg under fasting conditions
Study: 36458443
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (R) of apixaban 2.5 mg under fed conditions
Study: 34533034
Drug: Experimental strategy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental strategy: 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy
Study: 34533034
Drug: Reference strategy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference strategy: 75 to 100 mg aspirin daily plus either 75 mg clopidogrel daily (for SCAD) or 90 mg ticagrelor twice daily (for ACS) for 12 months, followed by aspirin monotherapy for 12 months
Study: 32513294
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg daily for 3 days, then tapered down over 6 weeks)
Study: 34420373
Drug: Colchicine (2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (2-mg loading dose followed by 0.5 mg twice a day)
Study: 32639465
Drug: Daptomycin (once-daily,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (once-daily, age-adjusted doses)
Study: 34458925
Drug: 1% acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% acetaminophen gel
Study: 34458925
Drug: 2.5% acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% acetaminophen gel
Study: 34458925
Drug: 5% acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acetaminophen gel
Study: 34455556
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg as needed (PRN) for patients with 2-8 MMD
Study: 34455556
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg as needed (PRN) for patients with 9-14 MMD
Study: 34455556
Drug: Rimegepant on
Normalized name: Rimegepant only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant on a fixed every-other-day schedule plus as needed dose (QOD+PRN) for patients with 4-14 MMD
Study: 32255205
Drug: Ultrasound-guided betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided betamethasone injection with hydrodissection (5 mL)
Study: 32255205
Drug: Ultrasound-guided betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided betamethasone injection without hydrodissection (2 mL)
Study: 33812699
Drug: Ibuprofen (arginine)/tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (arginine)/tramadol 400/37.5 mg
Study: 33812699
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg alone
Study: 33812699
Drug: Ibuprofen arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginine 400 mg alone
Study: 36243225
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (n = 124) with shockable rhythm
Study: 36243225
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (n = 124) with non-shockable rhythm
Study: 36243225
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 132) with shockable rhythm
Study: 36243225
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 132) with non-shockable rhythm
Study: 33929523
Drug: CMR (Comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR (Comprehensive Medication Review)
Study: 32466773
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg magnesium oxide plus 150 mg zinc sulfate for 12 weeks
Study: 33536010
Drug: Ozone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (3 doses weekly)
Study: 33536010
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) (3 doses weekly)
Study: 33536010
Drug: Platelet Rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Rich Plasma (PRP) (2 doses with 3 weeks interval)
Study: 33536010
Drug: Plasma Rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Rich in Growth Factors (PRGF) (2 doses with 3 weeks interval)
Study: 35133411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and behavioral counseling
Study: 34074584
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg−1.kg−1 body mass)
Study: 38864155
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of β-lactam antibiotics
Study: 38864155
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of β-lactam antibiotics
Study: 34275099
Drug: Incretin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incretin-based therapy (sitagliptin followed by liraglutide)
Study: 34472504
Drug: Arterolane maleate
Normalized name: maleate
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg
Study: 33070154
Drug: JNJ‐42165279 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐42165279 (25 mg daily)
Study: 33162202
Drug: Oral pentavalent
Normalized name: rotavirus vacc, live oral pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentavalent rotavirus vaccine
Study: 33727659
Drug: 0.1% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bromfenac sodium ophthalmic solution
Study: 33727659
Drug: 0.02% fluorometholone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% fluorometholone ophthalmic suspension
Study: 34252034
Drug: Standard operation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard operation preparation procedure
Study: 36988361
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.3 mg
Study: 32606097
Drug: Chemotherapy (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + atezolizumab
Study: 32606097
Drug: Chemotherapy (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo
Study: 33802559
Drug: Progressive dynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive dynamic balance training (PDBT) with physical therapy
Study: 32976938
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg/Q3W)
Study: 32976938
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (gemcitabine or vinorelbine)
Study: 33319755
Drug: Early pregnancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pregnancy treatment (nutrition counseling, glucose monitoring, medications as needed)
Study: 33067279
Drug: Sulforaphane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane treatment for 12 weeks
Study: 33067279
Drug: Sulforaphane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane treatment
Study: 33006504
Drug: Ethanolic extract
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanolic extract of Opuntia ficus-indica var. saboten (OFE) administered for 12 weeks
Study: 32737350
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with LCPUFA (docosahexaenoic acid 300 mg/day, eicosapentaenoic acid 100 mg/day, arachidonic acid 120 mg/day)
Study: 33415379
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) injection (1-mL)
Study: 33415379
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) injection (0.5-mL)
Study: 33883048
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline oral care
Study: 36067479
Drug: Dehydrated human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (weekly and biweekly applications)
Study: 33617972
Drug: Supplement combination
Normalized name: dietary supplement combination no.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement combination (Boswellia serrata extract 250 mg/day, pine bark extract 100 mg/day, methylsulfonylmethane 1,500 mg/day, curcumin 168 mg/day)
Study: 33484397
Drug: Parent-delivered therapy
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-delivered therapy (5-week duration)
Study: 33678535
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP condition)
Study: 34319998
Drug: Prophylactic anticoagulants
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticoagulants (PAC)
Study: 34319998
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic anticoagulants (no PAC)
Study: 34319998
Drug: S/P-albumin <20g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/P-albumin <20g/L
Study: 34319998
Drug: S/P-albumin ≥20g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/P-albumin ≥20g/L
Study: 33235154
Drug: Short-course induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course induction chemotherapy (2 cycles of cisplatin 20 mg/m2 plus etoposide 40 or 100 mg/m2 for 5 days) followed by low-dose radiotherapy (dose: 2340 cGy) without a tumor bed boost
Study: 33235154
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy without a tumor bed boost
Study: 32975835
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg LSD
Study: 32975835
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg LSD
Study: 32975835
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg LSD
Study: 32975835
Drug: 5 µg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg, 10 µg, 20 µg LSD
Study: 33389959
Drug: Diabetic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic insulin users
Study: 33389959
Drug: Diabetic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic insulin users (male)
Study: 33389959
Drug: Diabetic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic insulin users (age 40-59)
Study: 33389959
Drug: Diabetic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic insulin users (2 to 4 years of morbidity)
Study: 36454874
Drug: Adolescents who
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents who self-reported to ever having had sex and used alcohol/drugs during their last sexual encounter
Study: 33290971
Drug: Phytosterol capsules
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol capsules (1.5 g/day)
Study: 33290971
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil capsules (2 g/day)
Study: 33306985
Drug: RBD monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD monoclonal antibodies
Study: 33028566
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (20 mg/kg for 3 days, followed by 10 mg/kg for a further 7 days)
Study: 33028566
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin and placebo
Study: 35365148
Drug: Glucose intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose intake group (75 g glucose)
Study: 35610083
Drug: Multi-disciplinary intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-disciplinary intervention including nutrition education using a smartphone game, aerobic exercise, and cognitive behavioral therapy (CBT)
Study: 32443319
Drug: UVA/riboflavin cross-linking
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA/riboflavin cross-linking (0.1% riboflavin solution for 10 minutes)
Study: 32443319
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (directly into corneal preservation solution)
Study: 35837807
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) in AIDP subtype
Study: 35837807
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) in AMAN subtype
Study: 33222598
Drug: High Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Lp(a) group (≥60 mg/dL)
Study: 33222598
Drug: Low Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Lp(a) group (<60 mg/dL)
Study: 33638625
Drug: Fexofenadine/pseudoephedrine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine/pseudoephedrine combination tablet (F/P)
Study: 32822600
Drug: Nitisinone 10
Normalized name: nitisinone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitisinone 10 mg daily
Study: 32795925
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d antofloxacin (AT)
Study: 32795925
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d antofloxacin (AT)
Study: 32795925
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d moxifloxacin
Study: 33275787
Drug: Tele‐PST (problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele‐PST (problem-solving therapy tele-delivered by licensed clinicians)
Study: 34526104
Drug: Kabasura Kudineer
Normalized name: Kadsura coccinea whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabasura Kudineer (KSK) 60 mL twice daily for 7 days
Study: 34526104
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 60,000 IU daily and zinc 100 mg daily for 7 days (Control)
Study: 33599086
Drug: Warm humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm humidified CO2 (WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 33599086
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure (non-WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 32986087
Drug: Early introduction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early introduction group (EIG) consuming 2.66 (1.85) g/wk of gluten from age 4 months.
Study: 32986087
Drug: Standard introduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard introduction group (SIG) consuming 0.49 (1.40) g/wk of gluten between ages 4 and 6 months.
Study: 34617003
Drug: standard-dose CS
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose CS
Study: 34617003
Drug: standard-dose CS
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose CS plus EEN (Modulen 1.5 kcal)
Study: 32545539
Drug: Intervention small
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention small group social networks (10 participants, 12 weekly sessions)
Study: 34000251
Drug: Estetrol (E4)
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg
Study: 36075994
Drug: S1 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S1 maintenance therapy (MT)
Study: 36075994
Drug: non-maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-maintenance therapy (non-MT)
Study: 32929634
Drug: Elderberry extract
Normalized name: elderberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderberry extract (15 ml orally twice a day for 5 days for ages 5-12; 15 ml 4 times a day for 5 days for > 12 years)
Study: 36242718
Drug: Deutetrabenazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (mean dose at week 8: 38.1 mg for Rollover; 36.5 mg for Switch)
Study: 36242718
Drug: Deutetrabenazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (mean dose across cohorts after titration: 37.6 mg; final visit mean dose: 45.7 mg)
Study: 34130688
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract (Abnoba Viscum Q®) administered subcutaneously during chemoradiotherapy.
Study: 35094827
Drug: Solution-Oriented Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Oriented Therapy Programme (6 to 10 sessions)
Study: 34383607
Drug: Caffeine (5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg per kg of body mass)
Study: 33626213
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment (0.03%) application twice/day
Study: 33626213
Drug: Microneedling once/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling once/week and tacrolimus ointment application directly after microneedling and twice/day the rest of the week
Study: 33626213
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment application twice/day under occlusion by polyethylene foil
Study: 36416303
Drug: Group-Early Start
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-Early Start Denver Model (G-ESDM) in inclusive classrooms
Study: 36416303
Drug: Group-Early Start
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-Early Start Denver Model (G-ESDM) in specialised classrooms
Study: 34265007
Drug: Lorcaserin 20
Normalized name: lorcaserin 20 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 20 mg
Study: 616616941
Drug: Transition Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition Preparation Training Program (TPT)
Study: 32804345
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (500 UI/kg p.o. weekly)
Study: 32688398
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with steroids (triamcinolone)
Study: 32688398
Drug: LIA without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIA without steroids
Study: 35068454
Drug: Plasma L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma L-carnitine
Study: 35068454
Drug: L-carnitine addition
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine addition to conventional risk factors
Study: 35068454
Drug: Higher L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher L-carnitine and lower inflammatory status
Study: 37068889
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anaesthesia (TIVA)
Study: 32604288
Drug: Bilateral regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral regional maxillary nerve block (MNB) with 0.15 ml/kg of lidocaine clorhidrate 2% with epinephrine 1:50.000, under direct vision through the spheno palatine holes, before surgery.